Featured Studies

Researchers are studying the brain's response to language and sound. This study uses a repetitive transcranial magnetic stimulation (rTMS), an investigational form of brain stimulation, to measure how different parts of the brain communicate in teens with autism spectrum disorder (ASD). Findings from this study may aid in the development of possible future treatments.

Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.

Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.

A study at the National Institute of Mental Health (NIMH) is seeking healthy females aged 6-18 for a brain imaging study using MRI. Researchers aim to learn about brain anatomy and function, while advancing the understanding of behavior and mental health in children and young adults.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.